Benchmark: Telemedicine Prescribing of Controlled Substances: Fourth Temporary Extension through 2026

Take this benchmark to assess how much you would benefit from taking the course on the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for prescribing controlled medications.

This topic isn’t about memorizing legal text—it’s about making sound, defensible decisions in real clinical and operational situations when you prescribe controlled substances via telemedicine under a temporary extension.

By taking the benchmark, you’ll quickly see whether you can already navigate the key trade-offs the rule creates, such as:

• Access vs. risk: maintaining continuity of care while still meeting core safeguards (legitimate medical purpose, usual course of practice).
• Flexibility vs. consistency: choosing which authority applies (temporary extension vs. the Two Final Rules) and avoiding “mixing and matching” requirements.
• Speed vs. defensibility: selecting compliant telemedicine modalities and documenting decisions in a way that holds up under audit.

What you’ll get from the course if you need it:

• Clear decision paths for when and how telemedicine prescribing is allowed under the temporary extension.
• Practical compliance steps (technology, documentation, internal controls) that reduce enforcement exposure.
• Guidance on how this temporary extension interacts with other DEA/HHS rules so your team applies the right requirements in the right scenario.
• Preparation for transition planning as the temporary period ends, helping you avoid last-minute disruption for patients and staff.

If the questions feel uncertain or “it depends” in ways you can’t confidently resolve, that’s a strong signal the course will pay off in reduced compliance risk and smoother operations.